echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > "Pharmaceutical Headlineking" First Health Insurance Electronic Payment Landing "Golden Drug Generation" will disappear

    "Pharmaceutical Headlineking" First Health Insurance Electronic Payment Landing "Golden Drug Generation" will disappear

    • Last Update: 2020-07-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    (2020/06/08) China's pharmaceutical industry trend insight under the New Deal environment; "The golden drug generation" disappeared into a final decision; pangolins become a first-class protection of animals, where these traditional Chinese medicines go from, after the vaccine, China's new crown and antibody research also ranked among the world's leading levelsJunshi Bio announced on June 7 that its recombinant all-human anti-SARS-CoV-2 monoclonal antibody injection ("JS016"), jointly developed with the Institute of Microbiology of the Chinese Academy of Sciences, has been approved for phase I clinical trialands and completed the first trial of subjects at Huashan Hospital affiliated with Fudan Universityneutralizing antibody drugs may be one of the most effective responsesOn June 4,, Shanghai's first invoice from an electronic voucher for health insurance was issuedIt is expected that the end of June will be extended throughout the district, by the end of August to expand to the city-wideDo not use the health insurance card, only with mobile phone can brush health insurance to see a doctor, buy medicine, and the Internet hospital combination, but also online consultation, drug courier homeThe electronic voucher of medical insurance has laid a very good foundation for the direct settlement of medical treatment in different places and the development of Internet medical treatment, medical and e-commerce, and online insuranceThe health-care e-voucher may seem like an internal clearing system, but what really matters is the combination of the two departmentsthe promotion of the e-voucher of medical insurance is one of the key tasks of the National Health Insurance Administration in 2020in recent years, the promulgation and implementation of a series of new policies has brought about great changes in China's pharmaceutical industryAt the supply side, the pace of approval and listing of innovative drugs and the inclusion of medical insurance has been significantly accelerated, greatly enriching the clinical drug selection of Chinese patients, and shortening the return on investment cycle of research and development;the risk of developing new drugs remains highwith the East Sunshine drug Aiomeprazole magnesium intestinal capsules, Betpharmaceutical injection of Esomeprazole sodium has been approved, as well as a number of local band procurement of proton pump inhibitor drugs included, proton pump inhibitors again attracted market attentionAccording to The Net, sales of anti-peptic ulcer drugs at the end of public medical institutions in China in 2019 were RMB39,966 millionAnti-peptic ulcer drug products TOP10 are proton pump inhibitors, and sales are more than 1 billion yuan; in brand TOP10, Osekang's injectable omeprazole sodium with sales of 2.764 billion yuan ranked first, Zhengda Qing Pharmaceutical Group's injection of ameme ameprazole sales led with a growth rate of 23.28 percentThe results of the of drugs such as proton pump inhibitors are worthy of attention today, the Chongqing Municipal Health Insurance Bureau issued "on the gradual digestion of the local supplementof the list of health insurance Class B drugs in Chongqing." In the "PublicIty", Chongqing City issued the local supplement of the three-year digestion principle of the health insurance Class B drug, published the proposed three-year list of digested drugs, a total of 89, publicity period: June 8 - June 12 the large limit for local additions to opt out of health insurance is mainly concentrated at the end of June 2022 June 5, the National Health and Health Commission, the Ministry of Industry and Information Technology, the Ministry of Public Security, the Ministry of Finance, the Ministry of Commerce, the State Administration of Taxation, the State Administration of Market Supervision and Administration, the State Administration of Medical Security, the State Administration of Traditional Chinese Medicine and other nine ministries jointly issued the "Notice on the issue of 2020 to correct the pharmaceutical purchase and sale of the field and medical services in the main points of work." In particular, the Circular calls for the consolidation of the effectiveness of reforms in the field of pharmaceutical circulation The chain of further strengthening the management of pharmaceutical production and circulation is clarified In particular, the document states that violations in priority areas should be combated We will crack down on the collusion between pharmaceutical companies and contract marketing organizations (CSO) enterprises, the illegal act of fictitious fees being cashed out to pay for illegal marketing the business thinking of "heavy market light research and development" should be firmly abandoned Xinhua News Agency reported that China will be all species of pangolins by the state secondary protection of wildlife to the first level According to the Wildlife Protection Act, there are significant differences in the sentences for the protection of wild animals at the national level and the punishment of the state's secondary protection of wild animals As a Chinese medicine tablet still existing in the 2015 edition of the Pharmacopoeia, pangolin and its pangolin-containing Chinese medicine, later development and production, there will be a major change After all, for the capture, sale, acquisition and use of wild animals, the first-level protection of animals needs to be approved by the State Council, while the second-level protection of animals only needs provincial government approval whether the clinical significance of pangolins is irreplaceable needs further study adenosine is one of the important substances that produce tumor immunosuppression in the tumor microenvironment, which inhibits the immune activity of immune cells by binding to A2a receptors In the process of adenosine production, there are two important key links: 1 When the body has tissue disorders (e.g inflammation, malignant tumors, etc.), atap in the cell is released in large quantities outside the cell, these ATP will be external nucleotide hydrolysis CD39 hydrolysis into ADP and AMP; 2 AMP then in the synergy of CD73 down the phosphoric acid to produce immunosuppressive adenosine CD39 inhibitors have plenty to explore.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.